top of page

Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine

About the study

NCT Trial Number

NCT04216888

The drug being studied

Ketamine

noun_Drug_2240951.png
noun_Institution_118530.png

Sponsored by

Dan Iosifescu
Nathan Kline Institute for Psychiatric Research

noun_date_3237048.png

Trial Start Date

Jun-19

noun_capsule_138144.png

About the participants

Age seeking

18 Years to 65 Years

gender

All

noun_Mental Health_2683241.png

Primary condition of volunteers accepted

Depression

noun_square_138133.png

Accepts healthy volunteers?

No

This pilot study aims to identify predictors of response to intranasal ketamine treatment in patients with treatment-resistant depression.

Eyes Graffiti

Locations

United States, New York
Nathan Kline Institute
Orangeburg, New York, United States, 10962

Danielle Rette, PhD, MSW
845-398-7752
Danielle.Rette@NKI.rfmh.org

​

​

​

​

Get in contact

Find a study site convenient for you below, then email yourself the contact details and next steps

bottom of page